Tech Company Financing Transactions

Amicus Therapeutics Funding Round

Amicus Therapeutics, operating out of Cranbury, secured $55 million from Quaker Partners, Canaan Partners and CHL Medical Partners.

Transaction Overview

Announced On
9/8/2005
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Proceeds Purpose
The new funds will accelerate development of unique pharmacological chaperones to correct misfolded proteins.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Cedar Brook Dr.
Cranbury, NJ 08512
USA
Email Address
Overview
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. The Company has a robust development pipeline of treatments for a range of human genetic diseases.
Profile
Amicus Therapeutics LinkedIn Company Profile
Social Media
Amicus Therapeutics Company Twitter Account
Company News
Amicus Therapeutics News
Facebook
Amicus Therapeutics on Facebook
YouTube
Amicus Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Crowley
  John Crowley LinkedIn Profile  John Crowley Twitter Account  John Crowley News  John Crowley on Facebook
Chief Medical Officer
Jay Barth
  Jay Barth LinkedIn Profile  Jay Barth Twitter Account  Jay Barth News  Jay Barth on Facebook
Chief Operating Officer
Bradley Campbell
  Bradley Campbell LinkedIn Profile  Bradley Campbell Twitter Account  Bradley Campbell News  Bradley Campbell on Facebook
Chief Scientific Officer
Hung Do
  Hung Do LinkedIn Profile  Hung Do Twitter Account  Hung Do News  Hung Do on Facebook
Vice President
Jeffrey Castelli
  Jeffrey Castelli LinkedIn Profile  Jeffrey Castelli Twitter Account  Jeffrey Castelli News  Jeffrey Castelli on Facebook
VP - Finance
Daphne Quimi
  Daphne Quimi LinkedIn Profile  Daphne Quimi Twitter Account  Daphne Quimi News  Daphne Quimi on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/8/2005: MetaCarta venture capital transaction
Next: 9/8/2005: Cardiovascular Systems venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary